Zacks Investment Research·1d ago
Oscar Health, Inc. (OSCR) Stock Dips While Market Gains: Key FactsOscar Health, Inc. (OSCR) reached $29.9 at the closing of the latest trading day, reflecting a -3.05% change compared to its last close.
Oscar Health is experiencing a dramatic growth inflection, with revenue surging 70.4% YoY to $4.9B in 2026Q2 and achieving a record combined ratio of 84.8% in 2026Q1. However, the sustainability of this profitability is questionable, as the unusually low loss ...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | $1.10+173.0% vs $0.40 | $4.8B+1.3% vs $4.7B |
Q2 2026 May 6, 2026 | $2.07+71.1% vs $1.21 | $4.6B-6.4% vs $4.9B |
Q1 2026 Feb 10, 2026 | -$1.24-34.6% vs -$0.92 | $2.7B-12.1% vs $3.1B |
Q4 2025 Nov 6, 2025 | -$0.53+3.6% vs -$0.55 | $3.0B-2.2% vs $3.1B |
Oscar Health, Inc. (OSCR) reached $29.9 at the closing of the latest trading day, reflecting a -3.05% change compared to its last close.
The healthcare sector has performed fairly well so far in 2026 due to several factors: GLP-1 medications continue to drive new business and interest, while groundbreaking AI applications help enhance and accelerate the drug discovery process. On top of that, potential mergers and acquisitions activity, as big pharmaceutical companies face a major patent cliff, could provide opportunities for new firms to stand out.
Oscar Health is rated a buy, targeting a $45-$49 fair value, driven by scalable growth and margin expansion in the ACA market. OSCR grew membership 60% while the overall ACA market contracted 13%, achieving a 30% market share and improving the medical loss ratio to 81.5%. Management guides for 2029 revenue CAGR above 20%, a 5-7% operating margin, and $4+ EPS, with the Lucie marketplace as a key incremental driver.
WOOF, FIVE and OSCR made it to the Zacks Rank #1 (Strong Buy) growth stocks list on September 25th, 2026.
Benchmark OSCR against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Oscar Health, Inc. (OSCR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $30.94 | $8.02B | -18.31 | 27.5% | -3.79% | -44.38% | — | |
| $4.38 | $2.27B | -25.76 | 40.34% | -0.74% | -5.38% | — | |
| $7.94 | $1.64B | -2145.95 | 46.06% | 0.89% | 20.02% | — | |
| $93.60 | $32.7B | 8.06 | 14.27% | 24.44% | 19.52% | — | |
| $12.87 | $1.94B | -1.88 | — | — | -1328.94% | — | |
| $0.73 | $30.68M | -0.54 | — | — | -106.96% | — |
Oscar Health, Inc. (OSCR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Oscar Health, Inc. (OSCR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 9, 2026·SEC
Jun 8, 2026·SEC
Get notified when OSCR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Oscar Health, Inc. (OSCR) stock FAQ — growth, dividends, profitability & financials explained
Oscar Health, Inc. (OSCR) grew revenue by 27.5% over the past year. This is strong growth.
Yes, Oscar Health, Inc. (OSCR) is profitable, generating $550.7M in net income for fiscal year 2025 (-3.8% net margin).
Oscar Health, Inc. (OSCR) has a return on equity (ROE) of -44.4%. Negative ROE indicates the company is unprofitable.
Oscar Health, Inc. (OSCR) has a combined ratio of 103.4%. A ratio above 100% means claims and expenses exceed premiums.
